Fuji Pharma Co Sustainability Profile
Fuji Pharma Co., Ltd., commonly referred to as Fuji Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1950, the company has made significant strides in developing innovative healthcare solutions, primarily focusing on prescription pharmaceuticals and over-the-counter products. With a strong operational presence across Asia, Fuji Pharma is renowned for its commitment to quality and research-driven development. The company’s core offerings include a diverse range of therapeutic agents, particularly in the fields of oncology and infectious diseases, distinguished by their efficacy and safety profiles. Fuji Pharma has garnered recognition for its robust market position, consistently achieving milestones that underscore its dedication to advancing healthcare. Through a combination of cutting-edge technology and a patient-centric approach, Fuji Pharma continues to enhance its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Fuji Pharma Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fuji Pharma Co's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fuji Pharma Co's reported carbon emissions
In 2022, Fuji Pharma Co., headquartered in Japan, reported total carbon emissions of approximately 306,558,000 kg CO2e. This figure includes 6,044,000 kg CO2e from Scope 1 emissions, 8,153,000 kg CO2e from Scope 2 emissions, and a significant 292,361,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming for carbon neutrality by 2050. In the near term, Fuji Pharma has established Science Based Targets Initiative (SBTi) targets to reduce absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline. Additionally, they aim to cut Scope 3 emissions from purchased goods and services by 25% within the same timeframe. These targets reflect Fuji Pharma's commitment to aligning with global climate goals, particularly those necessary to limit warming to 1.5°C. The company is actively working towards these objectives, demonstrating a proactive approach to managing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 5,261,000 | 0,000,000 |
| Scope 2 | 7,253,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 |
How Carbon Intensive is Fuji Pharma Co's Industry?
How Carbon Intensive is Fuji Pharma Co's Location?
Fuji Pharma Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fuji Pharma Co has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Fuji Pharma Co's sustainability data and climate commitments